Press Release

Eurocor's DEBIFU Registry successfully enrolled first patients

Bonn, Germany – September 24, 2012 – Eurocor GmbH is pleased to announce the successful start of the DEBIFU registry. This prospective multicenter national registry is designed to assess the safety and efficacy of the drug-eluting balloon DIOR® in the treatment of bifurcation lesions of all Medina classes. The widely used Medina classification provides a simple way to characterize the three sections of bifurcation lesions by using a binary system. A stenosis greater than 50% is coded as "1" and a stenosis less than 50% as "0". Accordingly a 1,1,1, bifurcation lesion shows a greater than 50% stenosis in the proximal main branch, the distal main branch and the side branch.

Under the direction of Principal Investigator (PI) Dr. Hubertus von Korn, Hospital Hetzelstift, Neustadt an der Weinstraße (Germany), this registry will enroll 100 patients at four German sites.

Primary endpoints of the registry are clinically driven or ischemia guided target lesion revascularization (TLR) and Major Adverse Cardiac Events (MACE) at 9 months follow up. Secondary endpoints include the frequency of technical aspects such as the incidences of additional stenting in the side or main branch or final kissing procedures. All four participating study sites have recently been initiated and started enrollment.

Dr. Pogge von Strandman, Vice President Clinical Department Eurocor GmbH, commented: "We are pleased to see an immediate response to the Registry announcement. So far we have 19 patients registered at the four study sites. With the special efforts of Dr. Hubertus von Korn and all other investigators involved, we are looking forward to the complete enrollment by the end of 2012."

-End-

Eurocor GmbH
One heartbeat ahead®

Eurocor GmbH
In den Dauen 6a
53117 Bonn
Germany

T + 49 (0) 228 20 1500
F + 49 (0) 228 20 1505
pressoffice@eurocor.de
eurocor.de

Eurocor is a wholly owned subsidiary of Opto Eurocor Healthcare and is part of the Opto Circuits Group – optocircuits.com

Media Contact
Eurocor GmbH
Claudia Tischendorf
Phone: +49 (0) 228 201 50 26
Email: pressoffice@eurocor.de

The Company:
Eurocor is a rapidly growing European Life Sciences Technology Corporation specializing in the research, development and manufacture of cardiovascular and endovascular products. Eurocor provides interventional physicians with innovative coronary stent technologies and special cardiovascular and endovascular devices, manufactured in Europe. Products are indicated for minimally invasive cardiovascular and peripheral surgery and comply with biological and biomechanical principles to offer highly flexible, adaptable solutions. Extensive research and development, close clinician collaboration, outstanding quality standard philosophy and global scientific alliances lead to optimization of clinically effective technologies. Eurocor has designed an innovative method for balloon catheter drug delivery with high patient compliance. One heartbeat ahead® – with innovative products such as DIOR® and FREEWAY™.
Eurocor GmbH is a wholly owned subsidiary of Opto Eurocor Healthcare Limited and is part of the Opto Circuits Group.
For more information, please visit eurocor.de and optocircuits.com.